Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting — Company to Host Webcast Presentation and Conference Call on Wednesday, June 1 — — Management Will Discuss Data and Study Design Details From FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 for the Treatment of Major Depressive Disorder — Alkermes plc (NASDAQ: ALKS) today announced that data and study design details from FORWARD-3 and FORWARD-4, two phase 3 studies of ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD), will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Scottsdale, Ariz. Management...
↧
